Kura Oncology Inc. (KURA) Downgraded by Zacks Investment Research to “Sell”
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
Separately, Oppenheimer Holdings Inc. restated an outperform rating and issued a $16.00 price target on shares of Kura Oncology in a research note on Sunday, August 14th.
Shares of Kura Oncology (NASDAQ:KURA) opened at 6.06 on Tuesday. The company has a 50 day moving average of $6.05 and a 200 day moving average of $4.11. The firm’s market cap is $113.58 million. Kura Oncology has a 52 week low of $2.50 and a 52 week high of $25.00.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Wednesday, August 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.02. On average, equities research analysts anticipate that Kura Oncology will post ($1.58) EPS for the current fiscal year.
A hedge fund recently bought a new stake in Kura Oncology stock. Alethea Capital Management LLC bought a new stake in shares of Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 62,000 shares of the company’s stock, valued at approximately $168,000. Alethea Capital Management LLC owned 0.34% of Kura Oncology at the end of the most recent quarter. 43.63% of the stock is owned by institutional investors.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.